Product Information
PRIMAQUINE 26.3 MG TABLET is a generic product labeled by Ingenus Pharmaceuticals LLC, priced at $1.9639 per EA under NDC 50742019105. Its NADAC has been published 91 times since Aug 21, 2024.
FDA first approved this application on Jun 23, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
15 mg/1
Manufacturer
Ingenus Pharmaceuticals LLCNDC
50742019105
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
5/21/2025
Active Ingredients
PRIMAQUINE PHOSPHATEApproval Type
Generic (ANDA)
FDA Application
ANDA206043FDA Approved
6/23/2016
TE Code
AB
On Market Since
1/23/2018
Pharmacological Classes
Price Statistics
The NADAC for PRIMAQUINE 26.3 MG TABLET has been published 91 times since Aug 21, 2024, and over the history we have for it it has risen 17.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.9639 per EA |
|---|---|
| All-time high | $1.9639 (May 13, 2026) |
| All-time low | $1.6638 (Oct 23, 2024) |
| 52-week high | $1.9639 |
| 52-week low | $1.9639 |
| Median price | $1.9639 |
| Average price | $1.8736 |
| Largest weekly change | +14.6% (Mar 19, 2025) |
| Weeks tracked | 91 |
| Tracking since | Aug 21, 2024 |
1W
N/A
1M
N/A
3M
N/A
6M
0.0%
1Y
0.0%
3Y
N/A
5Y
N/A
All
+17.9%
Last surveyed May 13, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the PRIMAQUINE PHOSPHATE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Ingenus Pharmaceuticals LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
PRIMAQUINE PHOSPHATE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Antimalarial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PRIMAQUINE 26.3 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for PRIMAQUINE 26.3 MG TABLET, manufactured by Ingenus Pharmaceuticals LLC, is $1.9639 per EA (NDC 50742019105), effective May 13, 2026.
How has the price of PRIMAQUINE 26.3 MG TABLET changed over time?
Over the history we have for it, the NADAC for PRIMAQUINE 26.3 MG TABLET has risen 17.9%. It has been tracked across 91 weekly CMS publications since Aug 21, 2024.
What are the highest and lowest recorded NADAC prices for PRIMAQUINE 26.3 MG TABLET?
Since Aug 21, 2024, the NADAC for PRIMAQUINE 26.3 MG TABLET has ranged from a low of $1.6638 (Oct 23, 2024) to a high of $1.9639 (May 13, 2026), with a median of $1.9639 per EA.
Are there cheaper alternatives to PRIMAQUINE 26.3 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of PRIMAQUINE 26.3 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures PRIMAQUINE 26.3 MG TABLET?
PRIMAQUINE 26.3 MG TABLET (NDC 50742019105) is labeled by Ingenus Pharmaceuticals LLC, and CMS classifies it as a generic product.